FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 583 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Oncotype DX Breast Cancer Test May Be Less Accurate for Black... February 26, 2021 Can Eating Grilled or Charred Foods Cause Cancer? January 10, 2023 News digest – cancer blood test, gum disease and junk food... July 25, 2020 Journalist Is Now Cancer-Free After Receiving Diagnosis On Facebook Live November 1, 2019 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... New on NCI Websites for December 2018
